Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL775810 | 0.90 | TAAR1 (0.38) | TAAR1SNCAALDH1A1HSD17B10CA2 | |
| SCHEMBL10598218 | 0.90 | SNCA (0.39) | TAAR1SNCAALDH1A1HSD17B10CA2 | |
| SCHEMBL10596213 | 0.86 | ALDH1A1 (0.41) | TAAR1SNCAALDH1A1HSD17B10CA2 | |
| SCHEMBL28542745 | 0.85 | CA2 (0.45) | TAAR1SNCAALDH1A1HSD17B10CA2 | |
| SCHEMBL4620923 | 0.85 | S1PR3 (0.43) | SNCAALDH1A1HSD17B10CA2LMNA | |
| SCHEMBL16028578 | 0.84 | CA2 (0.42) | SNCAALDH1A1HSD17B10CA2LMNA | |
| SCHEMBL10652394 | 0.84 | S1PR3 (0.45) | ALDH1A1CA2LMNAGAAMAPT | |
| SCHEMBL6259776 | 0.84 | S1PR3 (0.36) | TAAR1SNCAALDH1A1HSD17B10LMNA | |
| Ammonia Solution, Strong SCHEMBL28286823 | 0.84 | S1PR3 (0.42) | SNCAALDH1A1HSD17B10CA2LMNA | |
| SCHEMBL776515 | 0.83 | SNCA (0.39) | SNCAALDH1A1HSD17B10CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362192-A | PET radioactive tracer for imaging glycine transporter Glyt2 | 浙江颐核医疗科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | FIVE ELEVEN PHARMA INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4663637-A2 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | Five Eleven Pharma Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-114539243-B | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agent and pharmacological application thereof | 五一一制药股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117362192-A | PET radioactive tracer for imaging glycine transporter Glyt2 | 浙江颐核医疗科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-115536580-A | Deuterium substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110678465-B | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-114539243-A | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210346526-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | FIVE ELEVEN PHARMA INC. | 2021-11-11 | — | — | US | disclosed |
| EP-2012833-B1 | Radiolabeled dihydrotrabenazine derivatives and their use as imaging agents | UNIV PENNSYLVANIA (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2349352-B1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | SANOFI SA (FR) | 2013-12-25 | — | — | EP | disclosed |
| US-8562949-B2 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2604290-A2 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | The Trustees of The University of Pennsylvania (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120039816-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI-AVENTIS (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2349352-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINOÝ4,5-B¨INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI (FR) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049819-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B]INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-2012833-A2 | RADIOLABELED DIHYDROTETRABENAZINE DERIVATIVES AND THEIR USE AS IMAGING AGENTS | The Trustees Of The University Of Pennsylvania (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080050312-A1 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2007130365-A2 | RADIOLABELED DIHYDROTETRABENAZINE DERIVATIVES AND THEIR USE AS IMAGING AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | SLC18A2, SLC6A3, SLCO1B3 | TAAR1 220/4885SNCA 32/4885ALDH1A1 2065/4885 |
| US-20210346526-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | SLC18A2, SLC6A3, SLC6A2 | TAAR1 181/4885SNCA 12/4885ALDH1A1 1276/4885 |
| US-20080050312-A1 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | SLC18A2, SLC18A3, SLC6A2 | TAAR1 133/4885SNCA 184/4885ALDH1A1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.